Qualitative and quantitative comparison of cell-free DNA and cell-free fetal DNA isolation by four (semi-)automated extraction methods: impact in two clinical applications: chimerism quantification and noninvasive prenatal diagnosis.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
06 01 2021
Historique:
received: 24 09 2020
accepted: 10 12 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 15 5 2021
Statut: epublish

Résumé

Non-invasive molecular analysis of cell-free DNA (cfDNA) became a sensitive biomarker for monitoring organ transplantation or for detection of fetal DNA (cffDNA) in noninvasive prenatal test. In this study, we compared the efficiencies of four (semi)-automated cfDNA isolation instruments using their respective isolation kit: MagNA Pure 24 (Roche®), IDEAL (IDSolution®), LABTurbo 24 (Taigen®) and Chemagic 360 (Perkin Elmer®). The cfDNA was isolated from 5 plasma samples and the Rhesus D (RhD)-cffDNA from 5 maternal plasmas. The cfDNA were quantified by digital droplet PCR (ddPCR), BIABooster system and QUBIT fluorometer. The cfDNA fragment size profiles were assessed by BIABooster system. Chimerism were quantified by home-made ddPCR and Devyser NGS kit. RhD-cffDNA in maternal plasma were detected between weeks 14 and 24 of amenorrhea using free DNA Fetal RHD Kit® (Biorad®). Statistical tests have shown differences in DNA yield depending on the isolation procedure and quantification method used. Magna Pure isolates smaller cfDNA fragment size than other extraction methods (90% ± 9% vs. 74% ± 8%; p = 0.009). Chimerism was only reliable from LABTurbo 24 extractions using the NGS but not with ddPCR whatever extraction methods. RhD-cffDNA were detected by all isolation methods, although IDEAL and LABTurbo 24 systems seemed more efficient. This comparative study showed a dependency of cfDNA yield depending on isolation procedure and quantification method used. In total, these results suggest that the choice of pre-analytical isolation systems needs to be carefully validated in routine clinical practice.

Sections du résumé

BACKGROUND
Non-invasive molecular analysis of cell-free DNA (cfDNA) became a sensitive biomarker for monitoring organ transplantation or for detection of fetal DNA (cffDNA) in noninvasive prenatal test. In this study, we compared the efficiencies of four (semi)-automated cfDNA isolation instruments using their respective isolation kit: MagNA Pure 24 (Roche®), IDEAL (IDSolution®), LABTurbo 24 (Taigen®) and Chemagic 360 (Perkin Elmer®). The cfDNA was isolated from 5 plasma samples and the Rhesus D (RhD)-cffDNA from 5 maternal plasmas. The cfDNA were quantified by digital droplet PCR (ddPCR), BIABooster system and QUBIT fluorometer. The cfDNA fragment size profiles were assessed by BIABooster system. Chimerism were quantified by home-made ddPCR and Devyser NGS kit. RhD-cffDNA in maternal plasma were detected between weeks 14 and 24 of amenorrhea using free DNA Fetal RHD Kit® (Biorad®).
RESULTS
Statistical tests have shown differences in DNA yield depending on the isolation procedure and quantification method used. Magna Pure isolates smaller cfDNA fragment size than other extraction methods (90% ± 9% vs. 74% ± 8%; p = 0.009). Chimerism was only reliable from LABTurbo 24 extractions using the NGS but not with ddPCR whatever extraction methods. RhD-cffDNA were detected by all isolation methods, although IDEAL and LABTurbo 24 systems seemed more efficient.
CONCLUSIONS
This comparative study showed a dependency of cfDNA yield depending on isolation procedure and quantification method used. In total, these results suggest that the choice of pre-analytical isolation systems needs to be carefully validated in routine clinical practice.

Identifiants

pubmed: 33407582
doi: 10.1186/s12967-020-02671-8
pii: 10.1186/s12967-020-02671-8
pmc: PMC7788686
doi:

Substances chimiques

Cell-Free Nucleic Acids 0
DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15

Références

Transfus Clin Biol. 2007 Dec;14(6):572-7
pubmed: 18375165
Ann Biol Clin (Paris). 2019 Dec 1;77(6):619-637
pubmed: 31859639
Transl Lung Cancer Res. 2016 Dec;5(6):665-672
pubmed: 28149760
Hum Immunol. 2017 Apr;78(4):342-349
pubmed: 28267558
Clin Chem. 2008 Oct;54(10):1664-72
pubmed: 18703764
Clin Chem. 2009 Nov;55(11):1958-66
pubmed: 19729469
Prenat Diagn. 2007 May;27(5):415-8
pubmed: 17286310
Oncotarget. 2017 Sep 21;8(49):86253-86263
pubmed: 29156792
Biol Proced Online. 2013 Feb 13;15(1):5
pubmed: 23406353
Pancreas. 1998 Jul;17(1):89-97
pubmed: 9667526
Am J Obstet Gynecol. 2012 Aug;207(2):137.e1-8
pubmed: 22742782
Clin Chim Acta. 2011 Nov 20;412(23-24):2085-8
pubmed: 21861994
Anal Chem. 2018 Mar 20;90(6):3766-3774
pubmed: 29498256
Clin Chem. 2006 Mar;52(3):379-82
pubmed: 16397013
Cancer Biol Ther. 2005 Feb;4(2):139-63
pubmed: 15725726
Sci Transl Med. 2010 Dec 8;2(61):61ra91
pubmed: 21148127
Tumour Biol. 2019 Aug;41(8):1010428319866369
pubmed: 31402761
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41
pubmed: 26460048
Int Rev Cytol. 1980;68:251-306
pubmed: 7014501
Anal Biochem. 2006 Nov 15;358(2):247-56
pubmed: 16942746
Adv Clin Chem. 2015;70:197-246
pubmed: 26231488
J Pharm Biomed Anal. 2009 May 1;49(4):997-1002
pubmed: 19217735
Cells. 2019 Oct 14;8(10):
pubmed: 31615102
Curr Opin Cardiol. 2017 May;32(3):308-315
pubmed: 28306671
Nucleic Acids Res. 1990 Mar 25;18(6):1415-9
pubmed: 2326186
J Mol Diagn. 2017 Jan;19(1):162-168
pubmed: 27865784
J Am Soc Nephrol. 2017 Jul;28(7):2221-2232
pubmed: 28280140

Auteurs

Pascal Pedini (P)

Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France. pascal.pedini@efs.sante.fr.

Hajer Graiet (H)

Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.

Laurine Laget (L)

Department of Immunohematology, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.

Lugdivine Filosa (L)

Department of Immunohematology, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.

Jade Chatron (J)

Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.

Nicem Cherouat (N)

Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.

Jacques Chiaroni (J)

Department of Immunohematology, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.
UMR 7268, ADÉS Aix-Marseille Université/EFS, CNRS, 27 Bd Jean Moulin, 13385, Marseille Cedex 05, France.

Lucas Hubert (L)

Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.

Coralie Frassati (C)

Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.

Christophe Picard (C)

Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.
UMR 7268, ADÉS Aix-Marseille Université/EFS, CNRS, 27 Bd Jean Moulin, 13385, Marseille Cedex 05, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH